News and Press Releases


July 29,
2010
  JT's Consolidated Financial Results Continued growth in International Tobacco Business(PDF file)

April 28,
2010
  JT's Consolidated Financial Results Exceeds the Original Forecast Announced in 'JT-11' Full Fiscal Year Ended March 31, 2010(PDF file)

February 9,
2010
  JT Increases Annual EBITDA Forecast by JPY 9 billion and Annual Net Income Forecast by JPY 14 billion(PDF file)

October 29,
2009
  JT Upwardly Revises Forecasted Annual EBITDA by JPY 30 billion and Net Income by JPY 8 billion(PDF file)

July 30,
2009
  JT has Embarked on a Solid Start to Achieving its Fiscal Year Outlook Ending March 31, 2010(PDF file)

April 30,
2009
  JT Posts Record Net Sales and EBITDA for the Fiscal Year that Ended March 2009(PDF file)

March 23,
2009
  Launch of REMITCH(R) CAPSULES 2.5 μg , new oral antipruritus drug

February 9,
2009
  JT Forecasts Record Net Sales and EBITDA for Full Fiscal Year Ending March 2009 Following Robust Nine-Month Consolidated Financial Results(PDF file)

January 21,
2009
  Manufacturing and marketing approval for REMITCH(R) CAPSULES 2.5 μg , oral antipruritus drug, in Japan

October 30,
2008
  JT Upwardly Revises Results Forecast and Announces Consolidated Financial Results for 6-Month Period that Ended September 30, 2008(PDF file)

September 25,
2008
  Merck & Co., Inc. and Japan Tobacco Inc. Sign Licensing Agreement for Novel Osteoanabolic Drug Candidate to Treat Osteoporosis(PDF file)

July 31,
2008
  JT Reports Consolidated Financial Results for the First Quarter that Ended June 30, 2008

May 1,
2008
  JT Reports Consolidated Financial Results For the Full Fiscal Year that Ended March 31, 2008

February 7,
2008
  JT Reports Consolidated Financial Results For the Nine-Month Period that Ended December 31, 2007

October 31,
2007
  JT Reports Consolidated Financial Results for the First Fiscal Half that Ended September 30, 2007

September 26,
2007
  JT and Torii Sign Licensing Agreement with Keryx for Development and Commercialization of Hyperphosphatemia Drug in Japan

August 9,
2007
  JT Announces its First-Quarter Consolidated Financial Results and Gallaher Integration Plan(PDF file)

April 27,
2007
  JT Reports Consolidated Financial Results for the Full Fiscal Year that Ended March 31, 2007(PDF file)

February 8,
2007
  JT Reports Consolidated Financial Results for the Nine-Month Period that Ended December 31, 2006 (PDF file)

December 28,
2006
  JT Announces Licensing Agreement for New Antibody Drug Candidate with MedImmune

November 28,
2006
  New Drug Application of Antipruritic Agent "TRK-820" for the Treatment of Severe Pruritus in Hemodialysis Patients in Japan

October 31,
2006
  JT Reports Consolidated Interim Financial Results For the First Fiscal Half that Ended September 30, 2006(PDF file)

July 31,
2006
  JT Reports Consolidated Financial Results for the First Quarter that Ended June 30, 2006(PDF file)

April 28,
2006
  JT Reports Consolidated Financial Results for the Full Fiscal Year that Ended March 31, 2006(PDF file)

April 18,
2006
  JT Concludes Licensing Agreement for a New Drug Candidate with GlaxoSmithKline

February 17,
2006
  JT Reports Consolidated Financial Results for the Nine Month Period That Ended December 31, 2005(PDF file)

October 31,
2005
  JT Reports Consolidated Interim Financial Results For the First Fiscal Half That Ended September 30, 2005(PDF file)

August 1,
2005
  JT Reports Consolidated Financial Results for the First Quarter that Ended June 30, 2005 (PDF file)

April 27,
2005
  JT Reports Consolidated Financial Results for the Fiscal Year that Ended March 31, 2005 (PDF file)

April 8,
2005
  JT and Torii Pharmaceutical to Launch New HIV Treatment Drugs in Japan

March 22,
2005
  JT Concludes License Agreement on JT's Anti-HIV drug with Gilead

March 16,
2005
  Toray, JT, Torii Pharmaceutical Agree Co-development and Marketing

February 17,
2005
  JT's consolidated Financial Results for the Nine-Month Period that Ended December 31, 2004 (PDF file)



©2007 Akros Pharma Inc. All rights reserved.